Financhill
Sell
27

TOVX Quote, Financials, Valuation and Earnings

Last price:
$1.17
Seasonality move :
27.37%
Day range:
$1.14 - $1.19
52-week range:
$1.14 - $17.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.90x
P/B ratio:
0.13x
Volume:
48.5K
Avg. volume:
130.7K
1-year change:
-91.69%
Market cap:
$3.2M
Revenue:
--
EPS (TTM):
-$33.18

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TOVX
Theriva Biologics
-- -$5.25 -- -8.25% $100.00
IBIO
iBio
-- -$0.46 -100% -89.82% --
MRK
Merck &
$16.5B $1.57 5.76% -15.62% $128.73
NBY
NovaBay Pharmaceuticals
$2.6M -$0.31 -60.77% -99.16% --
PDEX
Pro-Dex
$12.1M $0.29 -- -22.22% --
PTN
Palatin Technologies
-- -$0.51 -100% -25% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TOVX
Theriva Biologics
$1.14 $100.00 $3.2M -- $0.00 0% 0.90x
IBIO
iBio
$2.48 -- $22.7M -- $0.00 0% --
MRK
Merck &
$98.05 $128.73 $248B 20.56x $0.81 3.18% 3.95x
NBY
NovaBay Pharmaceuticals
$0.53 -- $2.6M -- $0.00 0% 0.06x
PDEX
Pro-Dex
$48.67 -- $158.6M 31.81x $0.00 0% 2.98x
PTN
Palatin Technologies
$0.97 -- $18.9M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TOVX
Theriva Biologics
-- -1.027 -- --
IBIO
iBio
4.41% 6.097 5.41% 3.89x
MRK
Merck &
46.15% 0.824 13.95% 0.88x
NBY
NovaBay Pharmaceuticals
4.54% 0.704 1.51% 0.75x
PDEX
Pro-Dex
30.4% 1.274 13.7% 1.89x
PTN
Palatin Technologies
-- -0.872 -- 0.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TOVX
Theriva Biologics
-- -$5M -- -- -- -$3.9M
IBIO
iBio
-- -$4.1M -90.99% -148.3% -1820.57% -$3.7M
MRK
Merck &
$12.6B $4B 15.67% 29.26% 26.54% $8.5B
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PDEX
Pro-Dex
$5.2M $3M 12.04% 16.73% 23.31% $1.5M
PTN
Palatin Technologies
$350K -$7.8M -- -- -2356.3% -$7M

Theriva Biologics vs. Competitors

  • Which has Higher Returns TOVX or IBIO?

    iBio has a net margin of -- compared to Theriva Biologics's net margin of -4444.57%. Theriva Biologics's return on equity of -- beat iBio's return on equity of -148.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$6.81 --
    IBIO
    iBio
    -- -$0.46 $22.3M
  • What do Analysts Say About TOVX or IBIO?

    Theriva Biologics has a consensus price target of $100.00, signalling upside risk potential of 7838.6%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that Theriva Biologics has higher upside potential than iBio, analysts believe Theriva Biologics is more attractive than iBio.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    1 0 0
    IBIO
    iBio
    0 0 0
  • Is TOVX or IBIO More Risky?

    Theriva Biologics has a beta of 1.329, which suggesting that the stock is 32.874% more volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

  • Which is a Better Dividend Stock TOVX or IBIO?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or IBIO?

    Theriva Biologics quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. Theriva Biologics's net income of -$7.7M is lower than iBio's net income of -$4M. Notably, Theriva Biologics's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 0.90x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    0.90x -- -- -$7.7M
    IBIO
    iBio
    -- -- $175K -$4M
  • Which has Higher Returns TOVX or MRK?

    Merck & has a net margin of -- compared to Theriva Biologics's net margin of 18.95%. Theriva Biologics's return on equity of -- beat Merck &'s return on equity of 29.26%.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$6.81 --
    MRK
    Merck &
    75.51% $1.24 $82.7B
  • What do Analysts Say About TOVX or MRK?

    Theriva Biologics has a consensus price target of $100.00, signalling upside risk potential of 7838.6%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 31.29%. Given that Theriva Biologics has higher upside potential than Merck &, analysts believe Theriva Biologics is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    1 0 0
    MRK
    Merck &
    16 7 0
  • Is TOVX or MRK More Risky?

    Theriva Biologics has a beta of 1.329, which suggesting that the stock is 32.874% more volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

  • Which is a Better Dividend Stock TOVX or MRK?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.18% to investors and pays a quarterly dividend of $0.81 per share. Theriva Biologics pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or MRK?

    Theriva Biologics quarterly revenues are --, which are smaller than Merck & quarterly revenues of $16.7B. Theriva Biologics's net income of -$7.7M is lower than Merck &'s net income of $3.2B. Notably, Theriva Biologics's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 0.90x versus 3.95x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    0.90x -- -- -$7.7M
    MRK
    Merck &
    3.95x 20.56x $16.7B $3.2B
  • Which has Higher Returns TOVX or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Theriva Biologics's net margin of -49.65%. Theriva Biologics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$6.81 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About TOVX or NBY?

    Theriva Biologics has a consensus price target of $100.00, signalling upside risk potential of 7838.6%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that Theriva Biologics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Theriva Biologics is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    1 0 0
    NBY
    NovaBay Pharmaceuticals
    0 0 0
  • Is TOVX or NBY More Risky?

    Theriva Biologics has a beta of 1.329, which suggesting that the stock is 32.874% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

  • Which is a Better Dividend Stock TOVX or NBY?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or NBY?

    Theriva Biologics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Theriva Biologics's net income of -$7.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Theriva Biologics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 0.90x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    0.90x -- -- -$7.7M
    NBY
    NovaBay Pharmaceuticals
    0.06x -- $2.4M -$1.2M
  • Which has Higher Returns TOVX or PDEX?

    Pro-Dex has a net margin of -- compared to Theriva Biologics's net margin of 16.56%. Theriva Biologics's return on equity of -- beat Pro-Dex's return on equity of 16.73%.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$6.81 --
    PDEX
    Pro-Dex
    34.58% $0.75 $44.4M
  • What do Analysts Say About TOVX or PDEX?

    Theriva Biologics has a consensus price target of $100.00, signalling upside risk potential of 7838.6%. On the other hand Pro-Dex has an analysts' consensus of -- which suggests that it could grow by 6.84%. Given that Theriva Biologics has higher upside potential than Pro-Dex, analysts believe Theriva Biologics is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    1 0 0
    PDEX
    Pro-Dex
    0 0 0
  • Is TOVX or PDEX More Risky?

    Theriva Biologics has a beta of 1.329, which suggesting that the stock is 32.874% more volatile than S&P 500. In comparison Pro-Dex has a beta of 0.559, suggesting its less volatile than the S&P 500 by 44.102%.

  • Which is a Better Dividend Stock TOVX or PDEX?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or PDEX?

    Theriva Biologics quarterly revenues are --, which are smaller than Pro-Dex quarterly revenues of $14.9M. Theriva Biologics's net income of -$7.7M is lower than Pro-Dex's net income of $2.5M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Pro-Dex's PE ratio is 31.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 0.90x versus 2.98x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    0.90x -- -- -$7.7M
    PDEX
    Pro-Dex
    2.98x 31.81x $14.9M $2.5M
  • Which has Higher Returns TOVX or PTN?

    Palatin Technologies has a net margin of -- compared to Theriva Biologics's net margin of -2357.27%. Theriva Biologics's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TOVX
    Theriva Biologics
    -- -$6.81 --
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
  • What do Analysts Say About TOVX or PTN?

    Theriva Biologics has a consensus price target of $100.00, signalling upside risk potential of 7838.6%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Theriva Biologics has higher upside potential than Palatin Technologies, analysts believe Theriva Biologics is more attractive than Palatin Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    TOVX
    Theriva Biologics
    1 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is TOVX or PTN More Risky?

    Theriva Biologics has a beta of 1.329, which suggesting that the stock is 32.874% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

  • Which is a Better Dividend Stock TOVX or PTN?

    Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TOVX or PTN?

    Theriva Biologics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Theriva Biologics's net income of -$7.7M is higher than Palatin Technologies's net income of -$7.8M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 0.90x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TOVX
    Theriva Biologics
    0.90x -- -- -$7.7M
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is down 2.13% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 2.88% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 6.16% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock